| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_397ef87ef600023fb14935804248590d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-15043
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2800-107
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0636
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-867
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-725
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12 |
| filingDate |
2019-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b2934757b7a24ad4c2d9c03c7e48dc5a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2696ddf447c1199262b0b41f2748ae10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ede9323b7b1263ee81ef679b45f73b4c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e8dbc6f8243433aee4704453e3df5c61
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3d2322af1e7369029c64d7906927f0cd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_568b86cee8a05e362549bd774ee0e92d |
| publicationDate |
2020-10-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-111748026-A |
| titleOfInvention |
A specific T cell receptor for EGFR L858R gene mutation and its application |
| abstract |
The present invention provides a specific TCR for EGFR L858R gene mutation and its application, the TCR has the property of binding the neoantigen peptide KITDFGRAK-HLA-A*1101 complex derived from EGFR L858R gene mutation, and the TCR comprises α Variable and constant regions of chains and beta chains. Such TCR-modified T cells have specific killing effect on HLA‑A*1101 tumor cells with EGFR L858R gene mutation. In addition, the present invention also provides a drug combination for treating a tumor involving the expression of the gene mutation, which has the characteristics of strong specificity and good effect of individualized treatment. |
| priorityDate |
2019-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |